bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystrophy.
12.07.2023
Supporting the next generation of synbio scientists with iGEM
bit.bio is partnering with the iGEM student competition, aimed at advancing the field of synthetic biology.
Synthetic biology: impacting drug discovery
Our CEO Mark Kotter talks to Drug Discovery World about different approaches to synthetic biology and its applications in drug dis...
Decoding Bio Snapshot - bit.bio featured
The Decoding Bio Snapshot profiles 40 companies operating at the intersection of computation and biology.
VibeCast podcast talks to CEO Mark Kotter about patients and therapies
The discussion covers regenerative medicine, cell therapies and how human cells can transform research and drug development.
.png)
proto.life feature on industrial manufacture of human cells
This in depth feature covers bit.bio's breakthrough reprogramming approach and ability to manufacture human cells at industrial sc...
The power of automation featured in Scientist Live
Kathryn Golden, SVP Technical Operations & Cell Manufacturing, discusses how our opti-ox technology lends itself to scale through ...
bit.bio is industrialising human cell manufacturing
Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...
iNews feature on consistency data presented at ISSCR by bit.bio
The piece covers bit.bio's breakthrough in industrialising the consistent manufacture of human cells and how this will transform h...